Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
Alemtuzumab, an anti-CD52 monoclonal antibody, is effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Common adverse effects include the development of autoimmune diseases, and Graves’ disease is one of the most frequent presentations. We report here a case of alemtuzumab-in...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publishing
2019-04-01
|
| coleção: | International Journal of Immunopathology and Pharmacology |
| Acesso em linha: | https://doi.org/10.1177/2058738419843690 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|